Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375825 | 0.90 | TSHR (0.50) | NPY5RTSHRCCNT1CDK9POLB | |
| SCHEMBL2493713 | 0.84 | TSHR (0.44) | NPY5RTSHRCCNT1CDK9POLB | |
| SCHEMBL16062693 | 0.84 | POLB (0.46) | NPY5RALDH1A1TSHRCCNT1CDK9 | |
| SCHEMBL894078 | 0.83 | ALDH1A1 (0.44) | ALDH1A1KDM4EPOLBAPEX1TDP1 | |
| SCHEMBL9500932 | 0.83 | RAB9A (0.58) | ALDH1A1POLBTDP1LMNAHDAC1 | |
| SCHEMBL23822678 | 0.82 | TSHR (0.43) | NPY5RTSHRCCNT1CDK9POLB | |
| SCHEMBL915242 | 0.82 | TSHR (0.43) | NPY5RALDH1A1TSHRKDM4ECCNT1 | |
| SCHEMBL1833048 | 0.81 | TAAR1 (0.44) | ALDH1A1TSHRKDM4EPOLBAPEX1 | |
| SCHEMBL578004 | 0.81 | TSHR (0.41) | NPY5RTSHRCCNT1CDK9POLB | |
| SCHEMBL13059994 | 0.81 | NPY5R (0.42) | NPY5RTSHRCCNT1CDK9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233901-A1 | ACTIVATORS OF PYRUVATE KINASE ISOFORM M2 AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025215110-A1 | NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2025-10-16 | — | — | WO | disclosed |
| EP-4558478-A1 | ARYL HYDROCARBON RECEPTOR AGONIST PRODRUGS AND METHODS OF USE THEREOF | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2025-05-28 | — | — | EP | disclosed |
| US-20250136556-A1 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | ALLIANTHERA BOSTON INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250034156-A1 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza | NOVARTIS AG (CH) | 2025-01-30 | — | — | US | disclosed |
| US-12159967-B2 | Nonaqueous electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-12-03 | — | — | US | disclosed |
| EP-4467198-A2 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS AND PRODRUGS THEREOF USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| EP-4430028-A2 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2024-09-18 | — | — | EP | disclosed |
| EP-3759113-B1 | 10-(DI(PHENYL)METHYL)-4-HYDROXY-8,9,9A,10-TETRAHYDRO-7H-PYRROLO[1',2':4,5]PYRAZINO[1,2-B]PYRIDAZINE-3,5-DIONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE ORTHOMYXOVIRUS REPLICATION FOR TREATING INFLUENZA | NOVARTIS AG (CH) | 2024-09-11 | — | — | EP | disclosed |
| US-12071441-B2 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | NOVARTIS AG (CH) | 2024-08-27 | — | — | US | disclosed |
| WO-2001032179-A1 | 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| EP-1065205-A1 | HETEROAROMATIC DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2001-01-03 | — | — | EP | disclosed |
| US-6166033-A | 2-carbonylthiazole derivatives and use of the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| CN-1237971-A | 2-carbonylthiazole derivatives and use of the same | TAISHO PHARMACEUTICAL CO LTD (JP) | 1999-12-08 | — | — | CN | disclosed |
| EP-0940401-A1 | 2-CARBONYLTHIAZOLE DERIVATIVES AND USE OF THE SAME | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1999-09-08 | — | — | EP | disclosed |
| CN-1184478-A | Thiazole derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 1998-06-10 | — | — | CN | disclosed |
| EP-0816362-A1 | THIAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-5242908-A | Of dna and rna | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-09-07 | — | — | US | disclosed |
| CN-1053793-A | Use the disease that benzylphosphonic acid derivatives for treatment is caused by virus | HOECHST AG (DE) | 1991-08-14 | — | — | CN | disclosed |
| EP-0440148-A1 | Use of benzylphosphonic acid derivates for the treatment of viral diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136556-A1 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | AHR, ARNT, NR1H2 | NPY5R 1446/4885ALDH1A1 469/4885TSHR 86/4885 |
| US-12071441-B2 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | MAVS, ZC3HAV1, EIF2AK2 | NPY5R 1131/4885ALDH1A1 2409/4885TSHR 3343/4885 |
| US-20250034156-A1 | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza | MAVS, ZC3HAV1, EIF2AK2 | NPY5R 1059/4885ALDH1A1 2395/4885TSHR 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.